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ABSTRACT
Introduction First- time traumatic anterior shoulder 
dislocation (TASD) is predominantly managed non- 
operatively. People sustaining TASD have ongoing pain, 
disability and future risk of redislocation. There are no 
published randomised controlled trials (RCTs) comparing 
different non- operative rehabilitation strategies to 
ascertain the optimum clinically effective approach after 
TASD.
Methods and analysis In this multicentre adaptive RCT, 
with internal pilot, adults with a radiologically confirmed 
first time TASD treated non- surgically will be screened 
at a minimum of 30 sites. People with neurovascular 
complications, bilateral dislocations or are unable to attend 
physiotherapy will be excluded.
Randomisation will be on a 1:1 treatment allocation, 
stratified by age, hand dominance and site. Participants 
will receive a single session of advice; or a single session 
of advice plus offer of further physiotherapy (maximum 
4 months). The primary analysis will be the difference in 
Oxford Shoulder Instability Score at 6 months. A sample 
size of a minimum of 478 participants will allow us to 
show a four point difference with 90% power.
An embedded qualitative study will explore the 
participants’ experiences of the trial interventions.
Ethics, registration and dissemination Funded by 
NIHR HTA (16/167/56), 1 June 2018; National Research 
Ethic Committee approved (18/WA/0236), 26 July 2018. 
First site opened 5 November 2018 and final results will 
be updated on trial registries and submitted to a peer- 
reviewed journal and will inform rehabilitation strategies 
after a TASD. Study Within A Trial (SWAT) funded by MRC 
(MR/R013748/1), 1 May 2019; registered on the MRC- 
HTMR All- Ireland Hub (reference number SWAT 121).
Trial registration number ISRCTN63184243. (Trial stage: 
Pre- results)
INTRODUCTION
The shoulder is the most frequently dislo-
cated joint; occurring in 8.2–23.9 per 
100 000 people per year.1 Traumatic anterior 
shoulder dislocations (TASDs) occur when 
excessive forces during a traumatic event 
displace the humeral head frontwards, out 
of the shoulder socket, resulting in the joint 
surfaces completely losing contact.1–3 They 
predominantly occur in men under 25 years 
during high- impact events and women over 
80 years during low- impact events.1
People sustaining TASD often have 
ongoing pain, disability and morbidity linked 
to redislocation and subsequent need for 
repeated management.1–3 Rehabilitation may 
reduce these events and restore a functional, 
painless shoulder through restoration of 
movement and retraining muscles.2 However, 
a Cochrane review has found no evidence 
to support this2; Dutch national guidelines 
explicitly do not refer to physiotherapy3 and 
UK guidelines cite referral ‘may be helpful’.1
This research protocol will investigate the 
hypothesis regarding the nature and extent 
of what physiotherapy is required for the 
management of patients following TASD with 
an embedded ‘Study Within A Trial (SWAT)’ to 
compare two strategies for retention of partic-
ipants in randomised controlled trial (RCTs).
RESEARCH QUESTIONS
RCT research question
In adults with first time TASD managed non- 
operatively does a single session of advice 
and course of physiotherapy improve the 
Oxford Shoulder Instability Score (OSIS) by 
Strengths and limitations of this study
 ► UK- wide trial across a minimum of 30 sites to opti-
mise external validity.
 ► Primary outcome measure is patient centred.
 ► The main limitation is that the intervention could not 
be blinded.
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a minimum of four additional points at 6 months when 
compared with a single session of advice only?
SWAT research question
Does making a courtesy introductory telephone call to 
recruited participants improve response rates to 6 months 




To quantify and draw inferences on observed differences 
in the OSIS score between a single session of advice and 
physiotherapy with a single session of advice only, for 
adults with first time TASD managed non- operatively, 
6 months postrandomisation.
RCT secondary objectives
 ► To estimate comparative cost- effectiveness (cost/
quality- adjusted life- years, QALY) of the two trial treat-
ments, from an National Health Service (NHS) and 
personal social services perspective.
 ► To determine the difference in complication rate 
(eg, shoulder redislocation) in the first 12 months 
between the trial treatment groups.
 ► To quantify and draw inferences between the func-
tional status (OSIS) of the trial treatment groups at 
6 weeks, 3 and 12 months.
 ► To quantify and draw inferences on observed differ-
ences in the functional status (Disabilities of the Arm, 
Shoulder and Hand) of between the trial treatment 
groups at 6 weeks, 3, 6 and 12 months.
 ► To quantify and draw inferences on observed differ-
ences of health- related quality of life (EQ- 5D- 5L) 
between the trial treatment groups at 6 weeks, 3, 6 and 
12 months.
 ► To qualitatively explore participants’ experiences of 
receiving the trial treatments and identify facilitators 
and obstacles to adhering to them.
SWAT primary objective
Evaluate the impact of making a courtesy call to newly 
recruited participants in the Acute Rehabilitation 
following Traumatic anterior shoulder dISlocAtioN 
(ARTISAN) trial on response rates to 6 months follow- up 
questionnaires compared with a written card with similar 
information.
SWAT secondary objectives
 ► Time to response to the questionnaires at each time 
points.
 ► Response rates at 6 weeks, 3, 6 and 12 months.
 ► Completeness of responses.
 ► Number of reminder notices required.
 ► Cost of intervention per participant.
METHODS AND ANALYSIS
Study design
Multicentre, adaptive, RCT with internal pilot and SWAT.
Outcome measures
Outcome measures will be collected at baseline (preran-
domisation) at the recruiting site and then at 6 weeks, 3, 
6 and 12 months centrally from Warwick Clinical Trials 
Unit (WCTU) by postal questionnaire, mobile applica-
tion, telephone or email.
RCT primary outcome
OSIS: Self- completed outcome measure containing 12 
questions (0–4 points each), with possible scores from 0 
(best function) to 48 (worst function).4 5 Questions relate 
to activities of daily living particularly relevant to patients 
exhibiting shoulder instability and has been designed to 
assess outcome of therapy.
RCT secondary outcomes
Disabilities of the Arm, Shoulder and Hand
Self- completed shortened version of the Disabilities of 
the Arm, Shoulder and Hand (QuickDASH) question-
naire. Uses 11 items to measure physical function and 
symptoms in people with any or multiple musculoskeletal 
disorders of the upper limb. Designed to help describe 
the disability experienced by people with upper- limb 
disorders and monitor changes in symptoms and func-
tion over time.6
EQ-5D-5L
Health- related quality of life measure consisting of five 
dimensions, each with 5 levels of response. Each combi-
nation of answers is converted into a health utility score. 
Gives a single preference based index value for health 
status that can be used for broader cost- effectiveness 
comparative purposes.7
Complications: Complications will be defined into 
three categories:
1. Predefined complications directly related to the 
interventions.
2. Predefined complications directly caused by the pri-
mary TASD event not identified by the initial assessing 
clinician, but subsequently identified.
3. Complications not related to the intervention or TASD 
event and will subsequently not be formally analysed 
or reported.
Resource use questionnaires
Primary health economic analysis will concentrate on 
direct intervention and healthcare/personal social 
services costs, while wider impact (societal) costs will be 
included within the sensitivity analyses.
Embedded qualitative interviews
A purposive sample, up to 50 participants, informed by 
treatment allocation, gender, age and outcome will be 
invited for one interview, to explore the participant expe-
rience of receiving the interventions and facilitators and 
obstacles to adhering to them.
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SWAT primary outcome
Response rate: Proportion of participants who return the 
questionnaire.
SWAT secondary outcomes
Time to response: Date of first sending questionnaire to 
date of questionnaire received by study team.
Completeness of responses: Number of missing items 
per questionnaire.
Number of reminder notices: Number of notices 
administered by the trial team.




A worthwhile difference from this intervention is four 
points on the OSIS.8 9 The SD of the OSIS 6 months after 
injury is 10 points.8 9 However, the literature has predom-
inantly included a young population, given that we will 
recruit a wider range of ages a larger SD is expected, 
therefore an SD of 12 is more likely. To show a four- 
point difference at 5% significance level with 90% power 
allowing a margin of 20% loss during the follow- up needs 
a minimum of 478 participants.5 9
SWAT sample size
The sample size for the SWAT is limited by the host trial 
sample size. The SWAT opened to recruitment after the 
internal pilot (50 participants), therefore, approximately 
428 participants (214 per group) are expected and would 
provide 90% power and 5% significance to detect differ-
ences in retention rates of approximately 11%.
Screening and eligibility
RCT screening and eligibility
Adults presenting at trial sites (NHS hospitals) with a 
first- time TASD, confirmed radiologically, managed 
non- operatively (decided by the treating clinician and 
patient) will be identified as potential participants. The 
site team will undertake eligibility checks and details will 
be entered on a monthly screening log.
Participants will be excluded if they have significant 
neurovascular complications; bilateral dislocations; 
have been randomised previously; unable to adhere to 
trial procedures or unable attend physiotherapy within 
6 weeks of injury.
All eligible participants will be provided with verbal 
and written information about the study. If eligible and 
willing to join the study, a consent form will be signed 
(see online supplemental material), followed by collec-
tion of baseline demographic data, preinjury and postin-
jury functional outcomes.
SWAT screening and eligibility
Participants recruited into ARTISAN, who consent to 




Participants will be randomised at the end of the initial 
advice session via a web- based system. Allocation conceal-
ment will be maintained by an independent rando-
misation team at WCTU, who will be responsible for 
generation of the sequence and will have no role in the 
allocation of participants. The treatment group will be 
allocated by computer using a minimisation algorithm 
with a random element and stratification by participant 
age (39 years old and under and 40 years old and over), 
hand dominance and recruiting site.
SWAT randomisation
Minimisation with a random factor will be used to avoid 
imbalance between the SWAT intervention arms. The 
allocation ratio will be 1:1 and stratified by the ARTISAN 
allocation arm. Allocation concealment will be main-
tained by an independent randomisation team who will 
be responsible for generation of the sequence and have 
no role in the allocation of participants.
Postrandomisation withdrawals
Participants may discontinue at any time without preju-
dice. Unless a participant explicitly withdraws consent, 
data will be collected until the end of the trial. For partic-
ipants explicitly withdrawing consent for follow- up proce-
dures, trial data obtained up until the point of withdrawal 
will be included. Participants will have the option to with-
draw from the trial- related questionnaires, but continue 
to provide routine NHS data for trial purposes. Partici-
pants who withdraw will not be replaced. Participants may 
be withdrawn from the trial at the discretion of the investi-
gator and/or trial steering committee for safety concerns.
Interventions
RCT interventions
The interventions will be reported in line with the 
template for intervention description and replica-
tion (TIDIER) and Consensus on Exercise Reporting 
Template (CERT) checklists.10 11 All participating centres 
will receive an initial training session from the trial team. 
Following this, a lead physiotherapist at each site will be 
identified to complete subsequent training of additional 
physiotherapists. This training will be supported with 
web- based materials and a trial intervention manual.
All participants will receive a period of initial immobili-
sation in internal rotation as per UK national guidelines, 
for a duration of up to 2 weeks from date of injury.1 At this 
time participants will be provided with a web- link to phase 
1 of the ARTISAN advice materials and provided with a 
paper- based booklet version covering:
 ► What has happened to me?
 ► What can go wrong?
 ► How do I stop this happening again?
 ► How long do I have to wear my sling?
 ► Should I move my arm?
 ► How do I control my pain?
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 ► When can I return to usual activities?
 ► What if something goes wrong?
All participants will subsequently receive an appoint-
ment for a physiotherapy advice session within 6 weeks 
of injury. At the first appointment, all participants will 
receive a single session of advice to aid self- management, 
lasting up to 1 hour and administered by an ARTISAN 
trained physiotherapist. Following routine assessment, 
the physiotherapist will deliver the above core set of inter-
vention components and in addition:
 ► Points of contact if complications occur or expected 
recovery times are not achieved.
 ► A core set of progressive phase 2 range of movement 
exercises and what they aim to achieve.
 ► Enhancing self- management behaviours through the 
addition of goal setting, exercise planning and diaries.
The physiotherapist will provide details of web- based 
materials, which will include all the core components 
above in written and video format, and will include a dedi-
cated area for participants to set goals and keep diaries. 
The physiotherapist will also inform the participants 
that the website resources contain phase 3 progressive 
strengthening exercises and what they aim to achieve and 
later stage phase 4 progression to aid return to sports. 
Participants will be offered paper- based alternatives.
Following completion of the first physiotherapy 
appointment, the participant will be randomised, allo-
cating them to this advice session alone or to this advice 
session plus the offer of additional physiotherapy.
Participants randomised to the advice session only, will 
only receive this physiotherapy intervention. However, 
if they are experiencing ongoing issues which are not 
improving, as part of the control intervention, the advice 
is for the participant to contact the clinic they attended or 
see their general practitione. If a participant follows this 
advice and self- initiates further physiotherapy, this will 
not be deemed a deviation from the protocol. However, if 
someone other than the participant initiates further phys-
iotherapy (another clinician) then this will be deemed a 
protocol deviation. This data will be collected as part of 
the trial dataset.
Participants randomised to receive additional physio-
therapy will be offered of at least one additional physio-
therapy session. Each additional session will last for up to 
30 min, over a maximum duration of 4 months from date 
of randomisation. The number and frequency of any addi-
tional sessions will be jointly agreed between the clinician 
and participant, in keeping with standard practice. The 
course of physiotherapy will involve teaching and super-
vising the ‘core set’ of progressive exercises offered to the 
control arm in addition to being able to tailor treatment 
as per their usual practice.
SWAT interventions
Participants will be randomised to receive either:
1. An introductory call within 2 weeks of being ran-
domised to include thanking participants; reminding 
them of their valuable contribution and that they will 
be contacted at 6 weeks and 3, 6 and 12 months; in-
forming them of when the trial results are expected 
and to contact the ARTISAN team if they have queries.
2. A postcard- sized handwritten card, with similar con-
tent as above, signed by the chief investigator and trial 
manager, posted to participants within 1 week of being 
randomised.
Fidelity and quality assurance of interventions
The trial team will implement a standardised approach 
of evaluating fidelity12 of direct observations and audio 
recordings (twice annually); and self- reporting of the 
trial interventions. Any issues will be discussed by the trial 
management group (TMG), who will recommend appro-
priate action such as feedback to sites and additional 
training. If issues are not resolved following recommen-
dations they will be escalated to oversight committees.
During site quality assurance visits the research teams 
will also be asked to provide radiological confirmation of 
the participants initial shoulder dislocation. If evidence is 
not found, participants will be withdrawn from the main 
trial sample, but will continue follow- up procures and 
retained as part of a pre- planned sensitivity analysis.
Blinding
As the type of rehabilitation used will be clear to the partic-
ipant, they cannot be blind to treatment. The treating 
clinician will also not be blind, but will take no part in 
follow- up processes, these will be managed centrally from 
the WCTU to reduce the assessment bias.
Adverse event management
Serious adverse events (SAEs) will be entered onto the 
SAE reporting form and reported to the central study 
team. SAEs that may be expected will be predefined and 
recorded on the participant’s follow- up questionnaire. 
SAEs that may be expected as part of a TASD are: damage 
to nerve or blood vessels, fractures, redislocation, torn 
ligaments or muscles, persistent exacerbation of shoulder 
pain, restriction of range of movement, adhesive capsu-
litis (frozen shoulder) and persistent instability. All SAEs 
will be reported to the sponsor (Warwick University and 
University Hospitals Coventry and Warwickshire), ethics 
committee and oversight committees.
End of trial
The trial will end when all participants have completed 
their 12- month follow- up. The trial will be stopped prema-
turely if mandated by the Ethics Committee; following 
recommendations from relevant oversight committees; 
or funding ceases.
Trial oversight
The TMG will meet monthly and report to the indepen-
dent trail steering committee (TSC) and data monitoring 
and safety committee (DMSC). The TSC and DMSC will 
hold meetings annually and be responsible for approval 
of the protocol, monitoring and supervising progress.
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Patient and public involvement
The clinical team consulted with patients when devel-
oping this project and subsequently we had a meeting 
with a group representing our target participants. We 
discussed experiences and expectations of services and 
plans for the trial. Service users’ perspectives were key 
in the development of this protocol. Patient and public 
involvement (PPI) membership is represented on TMG 
and TSC committees and have reviewed all study mate-
rials. PPI members of the team will contribute to dissemi-
nation on trial completion.
Analysis
RCT statistical analysis
The internal pilot will inform and test recruitment strate-
gies for the main trial in 12 sites over 6 months. A recruit-
ment rate of one participant per month per centre was 
estimated for the 6 months pilot phase, with 50 partici-
pants in total. The decision to progress to the main trial 
will be made based on predefined progression criteria. The 
criteria for continuing will be achievement of 75%–100% of 
the recruitment target; criteria for the need to review and 
amend trial procedures before continuing will be achieving 
50%–75% of the target; criteria for not proceeding will be 
achieving less than 50% of the target. These randomised 
participants will be retained in the final analysis.
A detailed statistical analysis plan which will be agreed 
with the DMSC prior to the analyses taking place. All data 
will be reported in accordance with the Consolidated 
Standards of Reporting Trials (CONSORT) statement. 
Baseline data will be summarised to check compara-
bility between treatment arms, and screening data will 
be checked to highlight any characteristic differences 
between those individuals in the study, those ineligible 
and those eligible but withholding consent.
The research team recognise the theoretical possibility 
of therapist effects. Here, we are randomising by indi-
vidual; it is the same therapist who will be seeing people 
in both arms of the trial, and the treatment is individually 
delivered ensuring there are no group effects. To keep 
presentation of key information as standard throughout 
the study, the initial therapist contact will be described 
in the study manual and will use supporting media. We 
intend to recruit from a minimum of 30 sites where there 
will be multiple therapists taking part over the course of 
the study (eg, sickness and holiday coverage). This gives 
the number of estimated therapist level clusters upwards 
of 60 and potential cluster sizes of around four partic-
ipants in each arm of the trial. With such small cluster 
sizes, even if there were to be important therapist effects, 
their effect on statistical power would be minimal.
To address the possibility that these might exist, a single 
interim analysis is preplanned to re- estimate the sample 
size. This will occur after approximately 200 partici-
pants have completed the 3 months follow- up question-
naire, while recruitment is still open. The pooled SD of 
the primary outcome and presence of therapist effects 
will be estimated by calculating the therapist intraclass 
correlation coefficient and its 95% CI. Models will not 
include treatment effects. A revised sample size calcula-
tion will be discussed with DMC and TSC and if appro-
priate, permission requested from the funder to adjust 
the sample size.
All primary analyses are planned to be on an intention- 
to- treat basis with secondary per protocol analyses. The 
main analysis will investigate differences in the primary 
outcome measure, 6 months after randomisation, between 
the two treatment groups. Unadjusted and adjusted 
regression analyses will be used to estimate the between 
group difference. The adjusted analyses will adjust for 
the stratification variables, baseline scores and any other 
clinically important variables. Since individual clinicians 
will treat only a small number of participants enrolled in 
the trial, we do not expect clinician- specific effects to be 
important in this study.
Descriptive statistics of functional outcome data (ie, 
QuickDash and EQ- 5D- 5L) at each time point will be 
constructed with between group analyses following the 
method set out for the primary analysis above. Patterns 
of recovery will also be explored. Secondary analyses will 
includeχ2 tests to compare the number of dislocations 
and other complications between allocation groups. For 
important complications (eg, dislocations), Kaplan- Meier 
curves of the time to complication will be constructed. 
If sufficiently large numbers of complication groups are 
observed, Cox regression models will be constructed to 
compare the time to complication in each arm. Temporal 
effects will be investigated using a multilevel model of all 
follow- up data.
Two prespecified subgroup analyses will be undertaken 
to assess whether there is evidence of differing interven-
tion effect: hand dominance (injured shoulder dominant 
arm vs injured shoulder is non- dominant arm and age 
(younger participants vs older participants). Because of 
the small sample size these analyses will be exploratory. 
The subgroup analyses will follow the methods described 
for the primary analysis, with additional interaction terms 
incorporated into the mixed- effects regression model 
to assess the level of support for these hypotheses. We 
will additionally present the main result separately for 
younger and older age groups for the benefit of future 
systematic reviewers who may be focused on different age 
groups. We will draw no inference from these analyses.
Careful monitoring of missingness and crossovers will 
be conducted. If judged appropriate, multiple imputation 
will be used to account for missing data, with all neces-
sary assumptions reported. If large numbers of treatment 
crossovers are observed, Complier- Average Causal Effect 
models will be used.
RCT health economic analysis
A prospectively planned analyses will be detailed in a 
health economic analysis plan, agreed with the DMSC. 
Analysis will be conducted from an NHS and personal 
social services perspective, with methods adhering to the 
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recommendations of the National Institute for Health 
and Care Excellence (NICE) reference case.13
Costs of the intervention groups will be estimated, 
reflecting resource inputs associated with rehabilitation 
and broader healthcare resource utilisation. Resource 
use associated with the index condition will be captured 
through routine health service data collection systems 
and participant questionnaires administered at each 
follow- up time point.
Unit costs will be estimated from local and national 
sources using established accounting methods, reflated 
to current prices. Health- related quality of life will 
be measured at baseline and at all follow time points 
using the EQ- 5D- 5L measure. Responses will be used to 
generate QALYs using the UK value set recommended by 
NICE guidance at the time of analysis.14
Within- trial analysis using bivariate regression of costs 
and QALYs, with multiple imputation of missing data, 
will inform a probabilistic assessment of incremental 
treatment cost- effectiveness. Missingness mechanisms 
will be explored and multiple imputation methods will 
be used where appropriate to avoid biases associated with 
complete case analysis. Findings will be analysed and visu-
alised in the cost- effectiveness plane, as cost- effectiveness 
acceptability curves, net monetary benefit and value of 
information analysis. Costs and outcomes arising during 
the trial will be undiscounted, reflecting the 12- month 
time horizon. Sensitivity analyses will be undertaken to 
explore uncertainties and to consider issues of generalis-
ability of the study.
SWAT analysis
All eligible participants will be included on an intention- 
to- treat basis, using two- sided statistical significance at the 
5% level. We will summarise baseline characteristics of 
participants by the type of SWAT intervention sent. An 
average cost per participant will be estimated for each 
SWAT intervention arm. For the primary outcomes of 
questionnaire response rates, the difference in propor-
tions will be calculated with 95% CIs, and the primary 
analysis will be a χ2 test to assess statistical association. 
Additionally, a logistic regression adjusting for age, gender 
and host trial treatment allocation will be performed to 
investigate the effects of these variables. A per- protocol 
analysis will also be performed.
The secondary outcome of time to questionnaire return 
will be assessed by a Kaplan- Meier curve and the SWAT 
interventions compared by log rank test. Cox regression 
will be applied adjusting for participant age, gender and 
host trial treatment allocation, and the effect of the inter-
vention reported. The requirement for any questionnaire 
return reminder will be analysed in the same way as the 
primary outcome).
Embedded qualitative study
Qualitative data will be analysed using the Framework 
method,15 which broadly includes data familiarisation; 
identifying a thematic framework; indexing; charting; 
mapping and interpretation. NVivo software will be used 
to facilitate this process. Researcher bias will be mini-
mised through regular cross- checking of data and find-
ings by members of the research team. Transcripts will 
be returned to participants (where necessary) providing 
them with the opportunity to check the transcripts for 
accuracy and authenticity and to offer any subsequent 
reflections. Quotes will be used as exemplars of key points 
in the writing up of these data. These qualitative data will 
be used to provide insight into participant’s experiences 
of the interventions to provide context to the quantitative 
results.
ETHICS AND DISSEMINATION
This study was funded by NIHR HTA (16/167/56), 1 
June 2018; National Research Ethic Committee approved 
(18/WA/0236), 26 July 2018. The first site opened to 
recruitment 5 November 2018. The SWAT was funded 
by MRC (MR/R013748/1), 1 May 2019 and registered 
on the MRC- HTMR All- Ireland Hub (reference number 
SWAT 121).
The trial will be conducted in full conformance with 
the principles of the Declaration of Helsinki and to Good 
Clinical Practice guidelines and comply with all appli-
cable UK legislation and Warwick University Standard 
Operating Procedures. The trial will be reported in line 
with the CONSORT statement.16
The results of this project will be disseminated through 
peer- reviewed journals, conference presentations among 
the orthopaedic and rehabilitation networks, policy- 
makers, patient- specific newsletters and local mecha-
nisms at all participating centres.
MAIN STRENGTHS AND LIMITATIONS
This is the first UK- wide multicentre RCT across a 
minimum of NHS 30 sites. The primary outcome measure 
is patient centred. The main limitation is that the inter-
vention could not be blinded.
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